| Company Name: |
T&W GROUP |
| Tel: |
021-61551611 13296011611 |
| Email: |
contact@trustwe.com |
Rezafungin manufacturers
- Rezafungin
-
- $189.00
-
2026-09-10
- CAS:1396640-59-7
- Purity: 99.87%
- Supply Ability: 10g
- Rezafungin
-
- $189.00
-
2026-05-15
- CAS:1396640-59-7
- Purity: 99.87%
- Supply Ability: 10g
- Rezafungin
-
- $1500.00
-
2025-06-25
- CAS:1396640-59-7
- Min. Order: 1KG
- Purity: 99.0% min
- Supply Ability: 100 tons min
Related articles - Uses and advantages of Rezafungin
- Rezafungin is a novel, once-weekly antifungal being developed for the treatment and prevention of serious fungal infections.
- May 11，2022
|
| | Rezafungin Basic information |
| Product Name: | Rezafungin | | Synonyms: | Rezafungin;SP-3025;long-lasting,infection,SP3025,CD 101,antifungal,Fungal,inhibit,echinocandin,CD-101,Inhibitor,Rezafungin,SP 3025;Echinocandin B, 1-[(4R,5R)-4-hydroxy-N2-[[4′′-(pentyloxy)[1,1′:4′,1′′-terphenyl]-4-yl]carbonyl]-5-[2-(trimethylammonio)ethoxy]-L-ornithine]-4-[(4S)-4-hydroxy-4-(4-hydroxyphenyl)-L-allothreonine]-;Bexagliflozin Impurity 38;Rezafungin, 10 mM in DMSO;1-[(4R,5R)-4-Hydroxy-N2-[[4′′-(pentyloxy)[1,1′:4′,1′′-terphenyl]-4-yl]carbonyl]-5-[2-(trimethylammonio)ethoxy]-L-ornithine]-4-[(4S)-4-hydroxy-4-(4-hydroxyphenyl)-L-allothreonine]echinocandin B (ACI) | | CAS: | 1396640-59-7 | | MF: | C63H85N8O17 | | MW: | 1226.41 | | EINECS: | | | Product Categories: | | | Mol File: | 1396640-59-7.mol |  |
| | Rezafungin Chemical Properties |
| InChIKey | LNFCWEXGZIEGJW-WIQSWMFQNA-O |
| | Rezafungin Usage And Synthesis |
| Description | Rezafungin is a novel, once-weekly antifungal being developed for the treatment and prevention of serious fungal infections.Rezafungin is a member of the echinocandin class of drugs. Echinocandins are considered the safest antifungal drugs available and are suggested by the Infectious Disease Society of America (IDSA) as first-line treatment for fungal infections. | | Uses | Rezafungin (CD-101) is a second generation echinocandin with a similar spectrum and mechanism of action. Along with fosmanogepix, ibrexafungerp, olorofim, and opelconazole, rezafungin heralds a new era in the treatment of fungal infections. | | Side effects | Adverse effects associated with the use of Rezzayo may include, but are not limited to, the following: hypokalemia, pyrexia, diarrhea, anemia, vomiting, nausea, hypomagnesemia, abdominal pain, constipation, and hypophosphatemia. | | Mechanism of action | Rezafungin is a semi-synthetic echinocandin. Rezafungin inhibits the 1,3-B-D-glucan synthase enzyme complex, which is present in fungal cell walls but not in mammalian cells. This results in the inhibition of the formation of 1,3-B-D-glucan, an essential component of the fungal cell wall of many fungi, including Candida species (spp.). Inhibition of 1,3-B-D-glucan synthesis results in concentration-dependent in vitro fungicidal activity against Candida spp., however, the clinical significance of this activity is unknown.
| | in vivo | Rezafungin (Biafungin) shows potent in vivo efficacy as prophylaxis against Pneumocystis in a mouse infection model[1]. | Animal Model: | C3H/HeN mice[1] | | Dosage: | 1 mg/kg | | Administration: | Intraperitoneal injection; once daily for 6 days | | Result: | Significantly reduced nuclei and asci burdens.
|
| | References |
[1] Syed, Yahiya Y. “Rezafungin: First Approval.” Drugs 83 9 (2023): 833–840.
[2] Desnos-Ollivier, Marie and Fanny Lanternier. “New antifungals development: rezafungin in candidiasis treatment.” Lancet Infectious Diseases 22 3 (2023).
|
| | Rezafungin Preparation Products And Raw materials |
|